Form D · Other Health Care
CB Pharma Acquisition Corp.
Burlington, MA · CIK 0001619551
Offering snapshot reported Dec 11, 2014 · SEC filing
- Reported sold
- $2.85M Offering amount: $2.85M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 26, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 11, 2014 | Initial | $2,850,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-229955
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| n/a | None |
Source: Form D, filed Dec 11, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| George C. Avgerinos | Executive |
| Adam J. Chill | Director |
| N/A Coronado Biosciences, Inc. | Promoter |
| Neil Herskowitz | Director |
| Arthur A. Kornbluth | Director |
| Lindsay A. Rosenwald | Director, Executive, Promoter |
| Michael S. Weiss | Director |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
24 New England Executive Park Suite 105
Burlington, MA, 01803
Burlington, MA, 01803